FACULTY COMMENTS
DR JAKUBOWIAK: This study shows that the combination of
lenalidomide (R) and dexamethasone (D) in patients who had
relapsed is superior across the board to the prior traditional
standard therapy, which was dexamethasone. RD was highly
superior to D for progression-free and overall survival. So this
is another study showing that more patients can be rescued
successfully from relapsing disease, and as a result more will
have their lives prolonged.
DR LONIAL: This was one of the trials used to obtain FDA
approval for lenalidomide/ dexamethasone in patients with
relapsed myeloma. An improvement was seen not only in
response rate but also in overall and progression-free survival.
Toxicities associated with RD were manageable, and the
incidence of DVT was relatively low. This is an important study,
as it clearly establishes the response rate and efficacy of RD in
relapsed myeloma.
| Table of Contents | Top of Page |
